Rupam Manna, Medical Oncologist, Entrepreneur, interested in Metabolism education and brain science, shared a post on X:
“HRD in Ovarian Cancer. HRR in Prostate Cancer. Why the Difference?
The answer lies in tumor biology.
Ovarian cancer:
The key clinical question is: Is the DNA repair pathway functionally impaired?
Homologous recombination deficiency (HRD) testing identifies both BRCA-mutant and BRCA-like tumors that may benefit from PARP inhibitor therapy.
Prostate cancer:
The key clinical question is: Which DNA repair gene is altered?
Homologous recombination repair (HRR) gene testing identifies actionable genomic alterations, including BRCA1, BRCA2, ATM, PALB2, CHEK2, and CDK12.
Different cancers require different biomarkers and answer different clinical questions.
This infographic provides a clear overview of an important concept for clinicians, highlighting the distinct roles of HRD and HRR testing in precision oncology.”
Other articles about Prostate Cancer on OncoDaily.